公开(公告)号：US20240092912A1

公开(公告)日：2024-03-21

申请号：US18281530

申请日：2022-03-09

申请人： BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

发明人： Björn FRENDÉUS ,  Linda MÅRTENSSON ,  Ingrid TEIGE ,  Mark CRAGG ,  Robert OLDHAM ,  Stephen BEERS ,  Ali ROGHANIAN

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/283 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507

摘要： The present invention generally relates to antibody combinations and uses thereof.

公开(公告)号：US20220259309A1

公开(公告)日：2022-08-18

申请号：US17627385

申请日：2020-07-17

申请人： BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

发明人： Björn FRENDÉUS ,  Ingrid TEIGE ,  Linda MÅRTENSSON ,  Ingrid KARLSSON ,  Mark CRAGG ,  Stephen BEERS ,  Robert OLDHAM

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.